Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis

Domaine:

healthcare

Type de record:

paper

Créateur:

AmyMarVic

Éditeur:

Ame

Hôte:

ABSTRACT The screening of a focused library identified FTY720 (Fingolimod; Gilenya) as a potent selective antitrypanosomal compound active against Trypanosoma brucei gambiense and T. brucei rhodesiense , the causative agents of human African trypanosomiasis (HAT). This is the first report of trypanocidal activity for FTY720, an oral drug registered for the treatment of relapsing multiple sclerosis, and the characterization of sphingolipids as a potential new class of compounds for HAT.

Optimization of pyrazolopyridine derivatives for the treatment of human African trypanosomiasis

Despite recent advances in the development of therapeutics for human African trypanosomiasis, new tr

Development of tetrahydroisoquinoline analogues: Towards a treatment for Human African Trypanosomiasis

This research describes the exploration of a new scaffold with the potential to be developed in to a

Pharmacokinetic-pharmacodynamic assessment of the safety of fexinidazole for the treatment of human African trypanosomiasis

Development of Reduced Peptide Bond Pseudopeptide Michael Acceptors for the Treatment of Human African Trypanosomiasis

Human African Trypanosomiasis (HAT) is an endemic protozoan disease widespread in the sub-Saharan re

PO 8421 LITERATURE REVIEW OF BIOMARKERS FOR HUMAN AFRICAN TRYPANOSOMIASIS POST-TREATMENT FOLLOW-UP

Introduction Human African trypanosomiasis (HAT) is caused by Trypanosoma bruce

Chemical Derivatization and Characterization of Novel Antitrypanosomals for African Trypanosomiasis

The search for novel antitrypanosomals and the investigation into their mode of action remain crucia